SignalMark Lung Marker

Empowering early-stage 
lung disease prevention

The first "all-in-one" surface marking
​and surgical localization tool

​There when you need it.
​Made for intraoperative visualization and imaging to aid
​in accurate lesion resection and removal confirmation.

Gone if you don't.
​Designed to resorb within eight weeks for unobstructed imaging.

Additional indications under review

SignalMark™ Platform Technology

A single marker with
​multiple detection capabilities

The only way to directly mark lesions without
​adding complexity and cost to care.

No spills.
​Reliable marking that limits diffusion and migration after implantation.

No quills.
​Visually distinct localization at the tissue surface,
without discomfort or painful dislodgement.

Expanded modalities in development

Clinical Performance

Easier and faster to find than leading tissue markers

"efficient intraoperative localization of
non-palpable breast and lung tumors"*

Unmistakable.
​​Significantly faster and more accurate intraoperative detection than leading breast tissue markers.*

Built to last.
​Distinctly visible in lung tissue 21 days after placement.*

Clinical studies under way

Voss, Rachel K., et al. “Doppler Ultrasound-Visible SignalMark™ Microspheres Are Better Identified than HydroMARK® Clips in a Simulated Intraoperative Setting in Breast and Lung Tissue.” Annals of Surgical Oncology, vol. 25, no. 12, 2018..

Team

Peter Klemm, PhD
Chief Executive Officer

Peter Klemm has over 25 years of leadership experience, building companies and creating markets for novel, high-value products. He has held numerous leadership positions in pharmaceuticals, medical device and molecular diagnostics at NuVasive, Applied Proteomics, Predictive Biosciences, GeneOhm Sciences, Becton Dickinson, Jomed, Gruenenthal GmbH and Hoechst AG (now Sanofi). 
Dr. Klemm qualified in veterinary medicine at the Justus Liebig university in Giessen and holds a PhD from the Institute of Pharmacology at the Johannes Gutenberg University in Mainz. He completed his post-doctoral fellowship at the William Harvey Research Institute in London with Sir John Vane.​

Bill Blair, BS
Co-Founder & CTO

Bill Blair was the co-founder
​and CTO of RF Surgical Systems, 
acquired by Medtronic.​

​Prior to RF Surgical, he held 
leadership and development
roles at Bell-Atlantic and innovative 
early phase tech startups in the
electronics and telecom companies.
He holds a BS in electrical engineering
​and applied physics from Case Western Reserve University and has authored numerous patents. 

Jeffrey Port, MD
Co-Founder

Dr. Jeffrey Port is a Professor of Cardiothoracic Surgery and 
Attending Surgeon at New York Presbyterian – Weill Cornell 
Medical Center in New York. 
He specializes in minimally 
invasive lung and esophageal
cancer surgery, and lung volume
​reduction in emphysema patients. ​

Dr. Port is also the co-founder of
RF Surgical Systems, acquired
by Medtronic.

Josh Baltzell, MBA
Outside Board Member

Josh Baltzell has over 20 years 
of experience in the healthcare 
industry. He currently serves as Venture Partner as Sightline 
Ventures and Split Rock Partners,
and was previously with St. Paul Venture Capital.

​Josh has prior experience in 
investment banking at Piper 
Jaffray, and has held various 
marketing and business
development roles at
Boston Scientific.

About

"Our mission is to improve cancer resection through localization that can be
visualized by all clinicians in a way that fits into their existing workflow."

Bill Blair, BS
Co-Founder & CEO

---

About View Point Medical

View Point Medical is a medical device and technology company dedicated to improving surgical outcomes using novel tissue markers that enable effective lesion localization in cancer care. The company’s core technology is SignalMark™, an implantable tissue marker platform designed to perform across a broad set of clinical applications and intraoperative scenarios under multiple modes of detection and imaging. View Point’s first product, the SignalMark™ Lung Marker, the first “all in one” bioresorbable lung surface marking and localization tool, received FDA clearance in December of 2018. The company is leveraging the SignalMark™ technology platform to deliver a portfolio of markers and detection devices that simplify the way clinicians mark, track and remove cancer across the ​treatment path.

​

About Localization

Localization is made by applying marking devices into or near lesions
to allow clinicians to mark, track, and remove cancer. 
​

• Localization is key to the effective removal of cancerous lesions
• Substantial peer-reviewed evidence as well as physician input demonstrates that poor localization affects treatment outcomes
• Current localization techniques add complexity, especially in
  minimally invasive surgery
• Good localization should improve outcomes and simplify care by interconnecting radiology, surgery and pathology through shared visualization of the marker

Contact Us

© 2019 View Point Medical, Inc.